Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin and Brentuximab Vedotin in Cutaneous T-cell Lymphoma
NCT02616965Phase 1Completed
- Sponsor
- Fox Chase Cancer Center
- Start
- Feb 2017
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of romidepsin and brentuximab vedotin in cutaneous T-cell lymphoma (CTCL), sponsored by Fox Chase Cancer Center. Primary endpoint: Maximum Tolerated Dose at 64 weeks. Started Feb 2017; status: completed.
02
Drugs
romidepsinbrentuximab vedotin
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02616965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616965.